Objective： To investigated whether erythropoietin （EPO） would promote the proliferation of human cancer cell line MCF-7, Panc-1 and HepG2 so as to determine whether EPO would result a worse prognosis to the patients with malignant diseases. Methods： We examined the growth inhibitory or promotional effect of EPO to MCF-7, Panc-1 and HepG2 by MTT assay. Then we examined the cell cycle of those cancer cell lines which was cultured with EPO and without EPO by FCM. Results： The results showed there was no significant growth inhibitory or promotional effect of EPO to MCF-7, Panc-1 and HepG2. The cell cycle of those cancer cell lines cultured with EPO also has no significant different to that of those cancer cell lines cultured without EPO. Conclusion： It is concluded that EPO has no promotion effect to the cancer cell lines＇ proliferation, and maybe will not result a worse prognosis to the patients with malignant diseases.
Objective: To approach the expressions of MDR1 and BCRP in breast cancer stem cells and differentiated cells. Methods: The breast cancer stem cells were separated from human breast cancer primary tissues and MCF-7 by flow cytometry. Then we measured the expressions of MDR1 and BCRP with different subset cells by Realtime-PCR. Results: Contrasted with breast cancer differentiated cells, the expressions of MDR1 and BCRP in breast cancer stem cells were higher (P < 0.01), and the proportion of stem cells rose after chemotherapy (P < 0.01). Conclusion: Contrasted with breast cancer differentiated cells, breast cancer stem cells have stronger ability of drug-resistance with higher level of multi-drug resistance genes, and it is one of key points for chemotherapy failure of breast cancer.
Zhi Li Chunping Liu Yanli He Jinghui Zhang Tao Huang
